<DOC>
	<DOCNO>NCT01613599</DOCNO>
	<brief_summary>This prospective observational study evaluate long-term safety MabThera/Rituxan ( rituximab ) participant granulomatosis polyangiitis ( Wegener 's ) microscopic polyangiitis . Data collect maximum 4 year participant initiate MabThera/Rituxan therapy physician accord prescribe information .</brief_summary>
	<brief_title>An Observational Study The Safety MabThera/Rituxan ( Rituximab ) Patients With Granulomatosis With Polyangiitis ( Wegener 's ) Microscopic Polyangiitis</brief_title>
	<detailed_description />
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Microscopic Polyangiitis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult participant , &gt; /= 18 year age Granulomatosis polyangiitis ( GPA ) microscopic polyangiitis ( MPA ) , accord Chapel Hill Consensus Conference Definitions MPA American College Rheumatology ( ACR ) Criteria Classification GPA Disease severity require rituximab treatment per investigator 's assessment Prior use rituximab ( except receive within 4 week screen ) Known hypersensitivity rituximab , component product , murine protein Pregnant breastfeed woman Diagnosis ChurgStrauss syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>